ArticleScientific reports2026
Performance of leading large language models in adhering to clinical guidelines for anaplastic thyroid cancer: a comparative study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaplastic thyroid cancer (ATC) is a rare, aggressive malignancy with poor prognosis. Adherence to guidelines from the National Comprehensive Cancer Network (NCCN), American Thyroid Association (ATA), and European Society for Medical Oncology (ESMO) is critical for optimal patient outcomes. As large language models (LLMs) increasingly enter clinical workflows, rigorous evaluation of their alignment with established guidelines is essential. We evaluated five leading LLMs for their ability to generate guideline-concordant responses to clinical questions about ATC. We conducted a comparative study in 2025 following TRIPOD-LLM (Transparent Reporting of a Multivariable Model for Individual Prognosis or Diagnosis, Large Language Models) guidelines. Seventy clinical questions of varying complexity were developed from ATA, NCCN, and ESMO guidelines. Three surgical oncology experts validated each question and subsequently evaluated responses from five LLMs: ChatGPT 4.1, ChatGPT 5, Gemini 2.5 Pro, Claude Sonnet 4, and DeepSeek R1. Each response was scored for relevancy, clarity, accuracy, and adequacy on a 5-point Likert scale. Inter-rater reliability was assessed using both intraclass correlation coefficients (ICC) and Gwet's AC2 with ordinal weights. Model comparisons used the Kruskal-Wallis test with Dunn's post-hoc analysis and Bonferroni correction. A pre-specified sensitivity analysis excluding the unblinded model (ChatGPT 5) was performed to confirm robustness. Significant performance differences emerged across all four metrics: accuracy (p = 0.007), adequacy (p = 0.003), clarity (p = 0.014), and relevance (p < 0.001). Gemini 2.5 Pro achieved the highest median accuracy (4.5), followed by DeepSeek R1 (4.4), while ChatGPT 4.1 scored lowest (4.0). ICC values ranged from 0.34 to 0.44 (poor to moderate), but Gwet's AC2 yielded substantially higher estimates of 0.61 to 0.73 (moderate to substantial agreement), reflecting the impact of restricted score range on conventional reliability metrics. The sensitivity analysis excluding ChatGPT 5 confirmed the performance hierarchy among blinded models, with significance preserved or strengthened across all four metrics. Leading LLMs show variable capacity to align with ATC clinical guidelines. While top-performing models hold promise as supportive tools, their inconsistencies across domains and complexity levels preclude autonomous clinical use. These models should serve strictly as decision aids under expert supervision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.